Prophylaxis of thrombotic complications in a pregnant patients with prosthetic heart valves

Cover Page


Cite item

Full Text

Abstract

In patients with prosthetic heart valves pregnancy and labor are associated with high risk. There are no established anticoagulation guidelines in pregnant women with mechanical heart valve prostheses. More often physiological hypercoagulable state during pregnancy can reveal acquired and/or inherited hemostasis abnormalities which were asymptotic before pregnancy. The presence in the history of patients the foetal loss syndrome, severe obstetric complications (severe preeclampsia, abruptio placenta, antenatal fetal death, feto-placental insufficiency), thrombosis events is an indication for the screening for genetic thrombophilia and antiphospholipid syndrome. The diagnosis of thrombophilia in patients with mechanical heart valve prostheses can explain the inefficiency of anticoagulation therapy, warfarin resistance, «floating» hemostasis markers and difficulties in adequate dose selection

About the authors

Aleksandr Davidovich Makatsariya

I. M. Sechenov 1-st Moscow State Medical University

Email: gemostasis@mail.ru
MD, PhD Professor, Correspondent Member of the RAMS, Head of the Chair of Obstetrics and Gynecology of Medical Prophylaxis Faculty

Viktoriya Omarovna Bitsadze

I. M. Sechenov 1-st Moscow State Medical University

Email: gemostasis@mail.ru
MD, PhD Professor of the Chair of Obstetrics and Gynecology of Medical Prophylaxis Faculty

Dzhamilya Khizriyevna Khizroyeva

I. M. Sechenov 1-st Moscow State Medical University

Email: gemostasis@mail.ru
MD, PhD, assistant of the Chair of Obstetrics and Gynecology of Medical Prophylaxis Faculty

Vyacheslav Borisovich Nemirovskiy

tate Clinical Hospital 67

head of the maternity hospital for pregnant women with cardivascular diseases

Svetlana Vladimirovna Akinshina

I. M. Sechenov 1-st Moscow State Medical University

Email: gemostasis@mail.ru
MD, PhD, assistant of the Chair of Obstetrics and Gynecology of Medical Prophylaxis Faculty

References

  1. Макацария А. Д., Бицадзе В. О. Тромбофилии и противотромботическая терапия в акушерской практике. — М.: Триада-Х, 2003. — 904 с.
  2. Смирнова Л. М. Беременность и роды после протезирования клапанов сердца: автореф. дис. … д-ра мед. наук. — М., 1994.
  3. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement / Turpie A. G. [et al.] // N. Engl. J. Med. — 1993. — Vol. 329, N 8. — P. 524–529.
  4. Anticoagulation in pregnant women with prosthetic heart valves / Elkayam U. [et al.] // J. Cardiovasc. Pharmacol. Ther. — 2004. — Vol. 9, N 2. — P. 107–115.
  5. Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy / Salem D. N. [et al.] // Chest. — 2004. — Vol. 126, N 3, suppl. — P. 457S–482S.
  6. Carpentier-Edwards standard porcine bioprosthesis: primary tissue failure (structural valve deterioration) by age groups / Jamieson W. R. [et al.] // Ann. Thorac. Surg. — 1988. — Vol. 46, N 2. — P. 155–162.
  7. Chan W. S., Anand S., Ginsberg J. S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature // Arch. Intern. Med. — 2000. — Vol. 160, N 2. — P. 191–196.
  8. Chesebro J. H., Adams P. C., Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves // J. Am. Coll. Cardiol. — 1986. — Vol. 8, N 6, suppl. B. — P. 41B–56B.
  9. Coumarins during pregnancy: long-term effects on growth and development of school-age children / Wesseling J. [et al.] // Thromb. Haemost. — 2001. — Vol. 85, N 4. — P. 609– 613.
  10. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves / Vitale N. [et al.] // J. Am. Coll. Cardiol. — 1999. — Vol. 33, N 6. — P. 1637–1641.
  11. Durability of the Hancock MO bioprosthesis compared with standard aortic valve bioprostheses / Yun K. L. [et al.] // Ann. Thorac. Surg. — 1995. — Vol. 60, N 2, suppl. — P. S221– 228.
  12. Effect of oral anticoagulant during pregnancy with prosthetic heart valve / Srivastava A. K. [et al.] // Asian Cardiovasc. Thorac. Ann. — 2002. — Vol. 10, N 4. — P. 306–309.
  13. Elkayam U., Bitar F. Valvular heart disease and pregnancy: part II: prosthetic valves // J. Am. Coll. Cardiol. — 2005. — Vol. 46, N 3. — P. 403–410.
  14. Frewin R., Chisholm M. Anticoagulation of women with prosthetic heart valves during pregnancy // Br. J. Obstet. Gynaecol. — 1998. — Vol. 105, N 7. — P. 683–686.
  15. Goldsmith I., Turpie A. G., Lip G. Y. Valvar heart disease and prosthetic heart valves // BMJ. — 2002. — Vol. 325, N 7374 — P. 1228–1231.
  16. Hirsh J. Guidelines for antithrombotic therapy. — 5th edition. — London: BC Decker Inc, 2005. — 121 p.
  17. Khamashta M. A. Hughes syndrome. Antiphospholipid syndrome. — 2nd edn. — London: Springer., 2006. — 598 p.
  18. Kutteh W. H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone // Am. J. Obstet. Gynecol. — 1996. — Vol. 174, N 5. — P. 1584–1589.
  19. Long-term performance of heart valve prostheses / Grunkemeier G. L. [et al.] // Curr. Probl. Cardiol. — 2000. — Vol. 25, N 2. — P. 73–154.
  20. Long-term survival and valve-related complications in young women with cardiac valve replacements / North R. A. [et al.] // Circulation. — 1999. — Vol. 99, N 20. — P. 2669–2676.
  21. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer / Lee A. Y. [et al.] // N. Engl. J. Med. — 2003. — Vol. 349. — P. 146–153.
  22. Medtronic intact porcine bioprosthesis: 10 years' experience / Jamieson W. R. [et al.] // Ann. Thorac. Surg. — 1998. — Vol. 66, N 6, suppl. — P. S118–121.
  23. Oran B., Lee-Parritz A., Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy // Thromb. Haemost. — 2004. — Vol. 92, N 4. — P. 747–751.
  24. Pregnancy and bioprostheses: influence on structural valve deterioration / Jamieson W.R. [et al.] // Ann. Thorac. Surg. — 1995. — Vol. 60, N 2, suppl. — P. S282–286.
  25. Pregnancy and childbearing in a population with biologic valvular prostheses / Badduke B. R. [et al.] // J. Thorac. Cardiovasc. Surg. — 1991. — Vol. 102, N 2. — P. 179–186.
  26. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves / Sadler L. [et al.] // BJOG. — 2000. — Vol. 107, N 2. — P. 245–253.
  27. Pregnancy outcomes in women with mechanical heart valves / Kim B. J. [et al.] // J. Reprod. Med. — 2006. — Vol.51, N 8. — P. 649–654.
  28. Prospective multicenter study of pregnancy outcomes in women with heart disease / Siu S. C. [et al.] // Circulation. — 2001. — Vol. 104, N 5. — P. 515–521.
  29. Rahimtoola S. H. Choice of prosthetic heart valve for adult patients // J. Am. Coll. Cardiol. — 2003. — Vol. 41, N 6. — P. 893–904.
  30. Risks of anticoagulant therapy in pregnant women with artificial heart valves / Iturbe-Alessio I. [et al.] // N. Engl. J. Med. — 1986. — Vol. 315, N 22. — P. 1390–1393.
  31. Spandorfer J., Konkle B., Merli G. J. Management and prevention of thrombosis in primary care. — New York: Arnold, 2001. — 349 p.
  32. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy // Eur. Heart J. — 2003. — Vol. 24, N 8. — P. 761–781.
  33. The effect of valvular heart disease on maternal and fetal outcome of pregnancy / Hameed A. [et al.] // J. Am. Coll. Cardiol. — 2001. — Vol. 37, N 3. — P. 893–899.
  34. Use of antithrombotic agents during pregnancy: the seventh ACCP Conference on antithrombotic and thrombolytic therapy / Bates S. M. [et al.] // Chest. — 2004. — Vol. 126, N 3, suppl. — P.627S–644S.

Copyright (c) 2012 Makatsariya A.D., Bitsadze V.O., Khizroyeva D.K., Nemirovskiy V.B., Akinshina S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies